Jeena Sikho dumps Entero, guides ₹300 cr profit for FY27
The hospital chain ended its exclusive distribution deal after Entero sought extra spending. Management set a ₹300 crore profit floor for next year, up from ₹222 crore in FY26.
— 2 earlier stories on Jeena Sikho Lifecare Ltd. →What's new
- Jeena Sikho ended its exclusive distribution deal with Entero after the partner demanded additional expenses.
- Management guided for a minimum ₹300 cr PAT in FY27, up from ₹222 cr in FY26.
- One-time charges of ~₹19 cr hit Q4 earnings; new product launches and a luxury Manali centre are planned.
Why this matters
Dumping a distribution partner mid-expansion is a strategic bet that the company can own its go-to-market for new products. The ₹300 crore floor is a clear upgrade from FY26's ₹222 crore, but it rests on adding beds and launching new lines this quarter. The one-time charges in Q4 explain a messy quarter, but the core question is whether the new self-funded model can scale faster than the Entero tie-up.
What we're watching
- Execution on the new product launches targeting fertility and women's health.
- The opening and early performance of the Manali luxury wellness centre.
- Bed capacity ramp against the March 2027 target.
The full read
Jeena Sikho has axed its exclusive distribution tie-up with Entero after the partner sought more spending. The decision, disclosed in its Q4 earnings call, forces the hospital chain to build its own distribution muscle just as it prepares to launch new products in fertility and women's health this quarter. Management set a ₹300 crore floor for FY27 net profit, up from FY26's ₹222 crore. Q4 itself was messy, weighed down by ~₹19 crore in one-time charges that the CFO flagged as non-recurring. The expansion plan is aggressive: beds are set to jump to 3,000-3,500 by March 2027 from 2,300, and a luxury wellness centre in Manali is on track for a July opening. The long-term target is ₹3,000 crore in revenue within 3-5 years. The Entero split is the company's biggest strategic move this year. It ties the company's growth more tightly to its own execution.
Questions answered
- Why did Jeena Sikho end the Entero distribution deal?
- The company said the deal was terminated because Entero demanded additional expenses that Jeena Sikho was unwilling to meet. The breakup forces the hospital chain to handle distribution for new products in-house.
- What did Q4 earnings look like?
- Q4 profit was depressed by about ₹19 crore in one-time items, including an ECL provision, leasehold adjustments, and ESOP accruals. The CFO described these as non-recurring.
- What is the scale of the expansion plan?
- Jeena Sikho plans to increase operational beds to 3,000-3,500 by March 2027 from the current 2,300. It is also launching new super-specialty products and opening a luxury wellness centre in Manali this July.
- How does the FY27 guidance compare to FY26?
- The ₹300 crore minimum PAT guidance represents a significant increase over FY26's ₹222 crore net profit. The long-term revenue target is ₹3,000 crore within 3-5 years.
Story so far
All notes on JSLL →- 8 Jun 2026 · 4:42 PM IST Jeena Sikho dumps Entero, guides ₹300 cr profit for FY27
- 6d ago Jeena Sikho kills Entero deal, guides ₹300 cr profit for FY27
- 9d ago Jeena Sikho profit jumps 178% to ₹222 cr as costs lag revenue surge